Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Partial seizures Age: Adult Condition: Adjunctive treatment |
Dose: Oral – 300 mg Frequency: twice daily initially Note: may increase at weekly intervals by 600 mg/day up to 1200 mg/day |
|
Indication: Partial seizures Age: Adult Condition: Monotherapy (if converting from other antiepileptic drugs) |
Dose: Oral – Initial: 300 mg Frequency: twice daily Note: increase by 600 mg/day every week up to 2400 mg/day; reduce and withdraw concomitant antiepileptic drugs over 3-6 weeks while reaching maximum oxcarbazepine dose in 2-4 weeks |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Partial Seizures (Adjunctive Treatment) Age: 2-4 years |
Dose: Oral – 8-10 mg/kg/day Frequency: divided every 12 hours Note: by mouth (oral); not to exceed 600 mg/day |
|
Indication: Partial Seizures (Adjunctive Treatment) Age: 2-4 years |
Dose: Oral – 16-20 mg/kg/day Note: by mouth (oral); May start with this dose; may titrate to higher dose over 2-4 weeks; not to exceed 60 mg/kg/day |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Adult Condition: Renal impairment |
Dose: Not specified Note: Decrease initial dose by 50%, titrate up slowly |
Administration
- May be taken with or without food
- Take at same times each day
Side Effect
- Dizziness (30-50%)
- Diplopia (30-50%)
- Headache (26-30%)
- Nausea/vomiting (26-30%)
- Nystagmus (26-30%)
- Somnolence (26-30%)
- Ataxia (10-30%)
- Abnormal gait (16-20%)
- Tremor (16-20%)
- Abdominal pain (11-15%)
- Fatigue (11-15%)
- Vertigo (11-15%)
- Vision abnormalities (11-15%)
- Dyspepsia (5-6%)
- Rash (4%)
- Insomnia (2-4%)
- Abnormal thinking (Less than 4%)
- Hyponatremia (1-3%)
- Muscle weakness (1-2%)
- Hypotension (Less than 2%)
- Speech disorder (1%)
- Asthenia
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Carbamazepine, Phenobarbitone, Phenytoin, Valproic acid
|
Reduced serum levels
|
|
CYP3A4 substrates
|
May reduce levels/effects
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.